Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children

27. oktober 2021 opdateret af: National Institute of Allergy and Infectious Diseases (NIAID)

A Randomized Trial of Two Saquinavir-Containing Combination Treatment Regimens in Children With HIV Infection

The purpose of this study is to determine the safety and effectiveness of a soft-gel capsule formulation of saquinavir (SQV-SGC), a protease inhibitor, when given in combination with other anti-HIV drugs.

SQV-SGC has been tested in adults for the treatment of HIV infection, but more information is still needed about SQV-SGC in children. Recent studies suggest that this soft-gel capsule form may be safer and more effective than other protease inhibitors.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Clinical trials in adults and children suggest that SQV-SGC has advantages over other protease inhibitors in terms of tolerability, safety, and effectiveness in patients who have failed therapy with other protease inhibitors. [AS PER AMENDMENT 11/24/99: Pharmacokinetic data from this study demonstrate lower than expected plasma SQV exposures, particularly in Arm 1. Based on these data, patients in the study will be offered the opportunity to adjust their doses. Ritonavir added to the Arm 1 regimen is expected to significantly increase SQV-SGC plasma levels and allow twice-daily dosing for SQV-SGC.]

Patients are randomized to one of two study arms. Patients in Arm 1 receive SQV-SGC plus two [AS PER AMENDMENT 11/24/99: one or two] NRTIs of choice. Patients in Arm 2 receive SQV-SGC plus NFV plus one or two NRTIs of choice. All participants are evaluated by physical examinations and laboratory tests during the study and are followed for incidence of death, cancer, or fetal abnormality. NRTIs are not provided as part of this study. [AS PER AMENDMENT 11/24/99: This study is closed to accrual. All subjects on follow-up (Cohort 1) are given the option of either discontinuing participation in ACTG 397 or participating in the next phase of the study (version 2.0). Those electing to continue participation constitute Cohort 1A. The adjusted Arm 1 regimen consists of SQV-SGC plus ritonavir plus one or two NRTIs. Ritonavir is not provided as part of this study. The Arm 2 regimen study drugs have not changed but the maximum allowable dose of SQV-SGC has increased from 1,200 mg twice-daily to 1,600 mg twice-daily. Participants continue to be followed with physical examinations and laboratory evaluations that include an intensive pharmacokinetics study on Day 14 of the new regimen.]

Undersøgelsestype

Interventionel

Tilmelding

50

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • Univ of Alabama at Birmingham - Pediatric
      • Birmingham, Alabama, Forenede Stater, 352330011
        • Univ of Alabama at Birmingham / Childrens Hosp of AL
    • California
      • Long Beach, California, Forenede Stater, 90801
        • Long Beach Memorial (Pediatric)
      • Los Angeles, California, Forenede Stater, 90033
        • Los Angeles County - USC Med Ctr
      • Oakland, California, Forenede Stater, 946091809
        • Children's Hosp of Oakland
      • San Francisco, California, Forenede Stater, 941430105
        • UCSF / Moffitt Hosp - Pediatric
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06504
        • Yale Univ Med School
    • District of Columbia
      • Washington, District of Columbia, Forenede Stater, 20060
        • Howard Univ Hosp
    • Florida
      • Miami, Florida, Forenede Stater, 33161
        • Univ of Miami (Pediatric)
      • Riviera Beach, Florida, Forenede Stater, 33404
        • Palm Beach County Health Dept
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30306
        • Emory Univ Hosp / Pediatrics
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • Cook County Hosp
      • Chicago, Illinois, Forenede Stater, 606143394
        • Chicago Children's Memorial Hosp
      • Chicago, Illinois, Forenede Stater, 60612
        • Univ of Illinois College of Medicine / Pediatrics
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 701122699
        • Tulane Univ / Charity Hosp of New Orleans
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • Univ of Maryland at Baltimore / Univ Med Ctr
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 021155724
        • Children's Hosp of Boston
      • Springfield, Massachusetts, Forenede Stater, 01199
        • Baystate Med Ctr of Springfield
    • Mississippi
      • Jackson, Mississippi, Forenede Stater, 39213
        • Univ of Mississippi Med Ctr
    • New Jersey
      • Newark, New Jersey, Forenede Stater, 071032714
        • Univ of Medicine & Dentistry of New Jersey / Univ Hosp
    • New York
      • Albany, New York, Forenede Stater, 12208
        • Children's Hosp at Albany Med Ctr
      • Bronx, New York, Forenede Stater, 10461
        • Bronx Municipal Hosp Ctr/Jacobi Med Ctr
      • Bronx, New York, Forenede Stater, 10457
        • Bronx Lebanon Hosp Ctr
      • Great Neck, New York, Forenede Stater, 11021
        • North Shore Univ Hosp
      • New York, New York, Forenede Stater, 10021
        • Cornell Univ Med College
      • New York, New York, Forenede Stater, 10032
        • Columbia Presbyterian Med Ctr
      • New York, New York, Forenede Stater, 10032
        • Incarnation Children's Ctr / Columbia Presbyterian Med Ctr
      • New York, New York, Forenede Stater, 10037
        • Harlem Hosp Ctr
      • Stony Brook, New York, Forenede Stater, 117948111
        • State Univ of New York at Stony Brook
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 191341095
        • Saint Christopher's Hosp for Children
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 294253312
        • Med Univ of South Carolina
    • Virginia
      • Richmond, Virginia, Forenede Stater, 23219
        • Med College of Virginia
    • Washington
      • Seattle, Washington, Forenede Stater, 981050371
        • Children's Hospital & Medical Center / Seattle ACTU
  • Puerto Rico
      • Bayamon, Puerto Rico, 00956
        • Ramon Ruiz Arnau Univ Hosp / Pediatrics
      • San Juan, Puerto Rico, 009367344
        • San Juan City Hosp
      • San Juan, Puerto Rico, 009365067
        • Univ of Puerto Rico / Univ Children's Hosp AIDS

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

3 år til 16 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

Your child may be eligible for this study if he or she:

  • Is HIV-positive.
  • Is 3 to 16 years of age (consent of parent or guardian is required).
  • Has an HIV level greater than 10,000 copies/ml.
  • Has never taken at least one of the following anti-HIV drugs: lamivudine, zidovudine, stavudine, or didanosine.
  • Is able to swallow capsules and tablets.

Exclusion Criteria

Your child will not be eligible if he or she:

  • Has cancer requiring chemotherapy.
  • Has an acute opportunistic (AIDS-related) infection requiring therapy.
  • Has had two or more episodes of moderate or severe diarrhea or vomiting in the 3 months prior to study entry.
  • Has ever taken SQV or NFV.
  • Is pregnant or breast-feeding.
  • Is taking certain medications, including those that would interfere with the study drugs.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Efterforskere

  • Studiestol: Courtney Fletcher
  • Studiestol: Mark Kline

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

  • Brundage RC, Kline MW, Lindsey J, Fenton T, Fletcher CV. Pharmacokinetics of saquinavir (SQV) with nelfinavir (NFV) or ritonavir (RTV) in HIV-infected children. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 728)
  • Kline MW, Fletcher CV, Lindsey JC, Fenton T. A randomized trial of two saquinavir (SQV-SGC)-containing combination treatment regimens in HIV-infected children. 7th Conference on Retroviruses and Opportunistic Infections. 2000 Jan 30-Feb 2 [Poster 694]
  • Kline MW, Fletcher CV, Lindsey JC, Fenton T. A randomized trial of combination therapy with saquinavir soft gelatin capsules (SQV) in HIV-infected children. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 683)
  • Brundage RC, Kline MW, Lindsey JC, Fenton T, Fletcher CV. Pharmacokinetics (PK) of saquinavir (SQV) and nelfinavir (NFV) in a twice-daily (BID) regimen in HIV-infected children. 7th Conference on Retroviruses and Opportunistic Infections. 2000 Jan 30-Feb 2 [Poster 718]

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studieafslutning (Faktiske)

1. april 2001

Datoer for studieregistrering

Først indsendt

2. november 1999

Først indsendt, der opfyldte QC-kriterier

30. august 2001

Først opslået (Skøn)

31. august 2001

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. oktober 2021

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. oktober 2021

Sidst verificeret

1. oktober 2021

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • ACTG 397
  • 11353 (Registry Identifier: DAIDS ES)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner